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Abstract
Although several genes are implicated in the pathogenesis of schizophrenia, in animal models for such a severe mental
illness only some aspects of the pathology can be represented (endophenotypes). Genetically modified mice are currently
being used to obtain or characterize such endophenotypes. Since its cloning and characterization CB1 receptor has
increasingly become of significant physiological, pharmacological and clinical interest. Recently, its involvement in
schizophrenia has been reported. Among the different approaches employed, gene targeting permits to study the multiple
roles of the endocannabinoid system using knockout (
-/-) mice represent a powerful model but with some limitations due to
compensation. To overcome such a limitation, we have generated an inducible and reversible tet-off dependent tissue-
specific CB1
-/- mice where the CB1R is re-expressed exclusively in the forebrain at a hypomorphic level due to a mutation
(IRh-CB1
-/-) only in absence of doxycycline (Dox). In such mice, under Dox
+ or vehicle, as well as in wild-type (WT) and CB1
-/-,
two endophenotypes motor activity (increased in animal models of schizophrenia) and pre-pulse inhibition (PPI) of startle
reflex (disrupted in schizophrenia) were analyzed. Both CB1
-/- and IRh-CB1
-/- showed increased motor activity when
compared to WT animals. The PPI response, unaltered in WT and CB1
-/- animals, was on the contrary highly and significantly
disrupted only in Dox
+ IRh-CB1
-/- mice. Such a response was easily reverted after either withdrawal from Dox or haloperidol
treatment. This is the first Inducible and Reversible CB1
-/- mice model to be described in the literature. It is noteworthy that
the PPI disruption is not present either in classical full CB1
-/- mice or following acute administration of rimonabant. Such a
hypomorphic model may provide a new tool for additional in vivo and in vitro studies of the physiological and pathological
roles of cannabinoid system in schizophrenia and in other psychiatric disorders.
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Introduction
Both genetic heterogeneity and clinical variability of schizo-
phrenia, the complex mental disorder affecting as many as 51
million people worldwide, make it difficult to elucidate the
neurobiological basis of clinical-association studies. Limited
knowledge of the underlying molecular mechanism of such mental
illness could be somewhat attributable to the difficulty in selecting
experimental models that truly mimic schizophrenia [1]. Although
several genes (including COMT, Dysbindin, Neuregulin, Synap-
sins, Arc, DISC etc.) have been implicated in its pathogenesis [2],
a reliable animal model for such a severe mental illness is still
lacking [3] and only some aspects of the pathology-endopheno-
types- have been represented [4,5].
Currently, genetically modified mice are being used to obtain or
characterize such endophenotypes providing a molecular specific-
ity impossible in human studies.
Since its cloning and characterization [6], CB1R has increas-
ingly become of significant physiological, pharmacological and
clinical interest. It represents the GPCR (G protein coupled
receptor), most expressed in the central nervous system and in the
periphery. The CB1R is an important component of the
endocannabinoid system (eCBS) along with the CB2R, the
endogenous cannabinoid ligands N-arachidonoylethanolamine or
anandamide and 2-arachydonylglycerol, and the enzymes respon-
sible for their synthesis and breakdown [7]. This system, and in
particular CB1R, has generated considerable research interest
both as a potential therapeutic target in the treatment of several
pathological conditions, from neurological and psychiatric disor-
ders to pain, metabolic syndromes and other diseases, as well as
addiction [8].
The strong link between several mental illnesses and the
cannabinoid system is widely documented [1]. CB1Rs are widely
distributed in brain areas such prefrontal cortex, hippocampus and
basal ganglia, all involved in schizophrenia In post-mortem studies
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protein expression as well as altered CB1R density in prefrontal
and cingulate cortices have been reported [9]. Moreover, several
epidemiological studies have shown an increased frequency of
cannabis abuse in schizophrenic patients (at least 50% of patients)
[1,3–5,10] as well as an increased incidence of psychotic symptoms
in people using it during adolescence [11–13]. A significant
association between a human CNR1 gene polymorphism and a
subtype of schizophrenia has been reported [14–15]. However,
contradictory reports have been published on the association of
CB1R gene polymorphism with schizophrenia and other authors
have failed to identify a statistically significant segregation of
CNR1 polymorphisms between schizophrenic patients and control
groups [14–17].
Schizophrenic patients have symptoms that are considered
positive (hallucination, delusions, disordered thinking and para-
noia) and negative (deficit in social interaction, emotional
expression and motivation). All the studies in animals, although
providing reliable data, suffer from the difficulty in selecting an
experimental model that resembles schizophrenia [1]. Moreover,
only in few papers the CB1R as well as the eCBS system have been
extensively examined in experimental (animal) models of schizo-
phrenia, and even less in mouse models. In rats all models were
based on the injection of PCP, a NMDA antagonist that induces
psychotic symptoms in humans. In these experiments the
dysregulation of CB1R in different brain areas is evident, but
the extent of its alteration, as well as the brain areas involved,
depends on the adopted model [1]. The few experiments carried
out on CB1 KO mice also were done using PCP injections. They
have shown that the CB1 gene disruption alters the behavioral
effects of PCP with a reduction of locomotion (increased in WTs)
and enhanced ataxia and stereotypy more than in controls,
without affecting social interaction [18]. Based on these results it
has been suggested that eCBS play different roles in negative and
positive symptoms, facilitating the formers and inhibiting the
latters. Furthermore, pharmacological studies, mostly on rats,
indicate that CB1R agonists can either reduce or have no effect on
positive symptoms induced by dopaminomimetic agents. On the
contrary, a non psychoactive component of C. Sativa as cannabidiol
dose-dependently inhibits the hyperlocomotion induced in mice by
ketamine [19]. Therefore, an adaptive/protective role of eCBS in
schizophrenia has been proposed [20]. Removing of eCBS control
through either the pharmacological blockade of CB1R or,
similarly, inducing its sensitization/internalization should enhance
the positive symptoms by reducing the inhibitory activity of eCBS
on dopaminergic pathways, thus worsening the symptoms [1].
Independently from experiments carried out using animal models
of schizophrenia, it must be underlined that an endocannabinoid
tone in the regulation of locomotor activity has been suggested by
the stimulating effect of the antagonist SR141716A per se and by
its ability in potentiating the locomotor stimulant effects of
amphetamine and apomorphine [21]. This hypothesis is supported
by the observation that locomotor activity is slightly increased in
mice without cannabinoid receptors [21]. However, another study
did not replicate this result and, on the contrary, a decrease in
open-field activity in the Zimmer’s CB1 knockout strain was found
[22]. These divergences have been explained by the biphasic
effects of cannabinoids depending on the level of the endogenous
tone, or by the observation that CB1 KO mice apparently have
higher levels of anxiety. The results may have been inuenced by
the experimental conditions (different intensity in illumination of
the open-field), low light condition being less anxiogenic for mice
that then exhibit higher locomotor activity [21].
Studies of sensorimotor gating of startle responses to strong
exteroceptive stimuli provide an excellent method for exploring
information processing and attentional deficits in schizophrenia.
Prepulse inhibition (PPI) is defined as the decrease in the
acoustic startle response when a non-startling prepulse is
presented before the startling pulse [23]. Chronic schizophrenic
and non-medicated first-episode schizophrenic patients have a
marked deficit in PPI. In rodents, as well as in human health
volunteers, such deficits can be obtained acting on different
neuronal systems through stimulation of the dopaminergic D2
receptors (with amphetamine or apomorphine), activation of
serotoninergic systems by direct 5-HT2A receptor agonists (with
LSD or psilocybin) and blockade of NMDA receptors by drugs
such as ketamine and PCP. Several studies show that the
CB1agonists may alter PPI however with not always concordant
results as CP55940 and WIN 55,212–2 reduced sensorimotor
gating in rats [24–25] but no changes in PPI after WIN
55,212–2 treatment, at whatever dosage and schedule were
observed in a different paper [26]. More recently it has been
reported in mice [27] that THC impaired PPI, while also
reducing the startle response. Moreover, the pretreatment with
typical (haloperidol) and atypical (risperidone) antipsychotics,
two potent dopamine D2 receptor antagonists, as well as the
CB1R antagonist SR141716 reversed the THC-induced PPI
deficit. However, in other studies in rats such ability of
SR141716 to revert the PPI deficits induced by dopaminergic
stimulation as well as the hyperlocomotion and stereotypy has
been questioned suggesting that blockade of the CB1 receptor
on its own is not sufficient for antipsychotic therapy [1].
Furthermore, one more study on rats reported that SR141716
behaves as an atypical antipsychotic since, similarly to
clozapine, it counteracted the PPI disruption produced by the
NMDA antagonists PCP and dizocilpine, and by apomorphine
[28]. Finally, it has been demonstrated [29] that SR141716
antagonized the disruptive PPI effects of apomorphine also in
mice. Moreover, Long and coworkers [30] showed that in mice
cannabidiol (CBD) significantly reversed PPI deficits induced by
MK-801 whereas did not affect PPI on its own. Because
clozapine (4 mg/kg) gave the same results, it was concluded that
CBD may have atypical antipsychotic potential. Thus, eCBS are
probably implicated in the negative regulation of dopamine
release by acting retrogradely on CB1 receptors in dopaminer-
gic presynaptic terminals lowering dopamine release [1].
Among the schizophrenia endophenotypes, the pre-pulse
inhibition (PPI) of the startle response is one of the most studied
and has been described in different transgenic mice [31].
Moreover, PPI experiments in CB1 knockout (
-/-) mice [32–35]
have never been performed, although a very recent paper
reporting the involvement of the CB2 receptor in such a
phenomenon has been published [10]. The aim of our study
was to investigate mainly the PPI response both in the
conventional CB1
-/- mice and in our temporal inducible-reversible
and tissue-specific hypomorphic model (IRh-CB1
-/-) in which the
CaMKIIa (Ca
2+/calmodulin-dependent kinase IIa) promoter [35]
modulates CB1R gene expression in specific brain areas. In these
transgenic mice, CB1 knockdown is achieved through the
Tetracycline-controlled transactivator (tTA) system and when
Dox is present, transcription is off [36–38]. In this system, the tTA
(deriving from the tetracycline resistance operon of E. Coli Tn10)
can be engineered under the control of tissue-specific or ubiquitous
promoters, while tetOpmin regulates the expression of a cDNA
cloned in cis, i.e., the gene of interest (when Dox is present,
transcription is off).
Disrupted PPI in Hypomorphic CB1
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Animals
FVB/N, C75BL/10 and CBA/J (Harlan Europe, Italy) used to
generate the transgenic line pBI-G-CB1 (see below) tTA-
CaMKIIa (originally bred on CD1 background mice were kindly
donated by Dr. Dan J Dumont, Molecular and Cellular Biology,
Sunnybrook & Women’s, Toronto) and CB1
-/- mice (originally
bred on C57BL/6J background were kindly donated by Dr. Aaron
H. Lichtman, Department of Pharmacology & Toxicology,
Virginia Commonwealth University) for behavioral experiments
were group-housed (2–3 animals per cage) in colony cages (Litter
Plus, SAFE, France) and maintained under standard conditions
(temperature of 2262uC, humidity 50%61) with a 12-h light-
dark cycle (lights on 07:00 am) with food (A04 feed, SAFE, France)
and water available ad libitum. All mutant lines were bred for .5
generations on the background of CBA/J-C57BL/10. CaMKII-
tTA
+/- and pBI-G-CB1
+/- littermates (originating after backcross-
ing the different genotypes in CBA/J-C57BL/10) were used as
wild-type (WT) for the behavioral and molecular experiments.
All procedures and experiments were carried out in an animal
facility according to Italian (D.L. 116/92 and 152/06) and
European Council directives (609/86 and 63/2010) and in
compliance with the approved animal policies by the Ethical
Committee for Animal Experiments (CESA, University of
Cagliari) and the Italian Department of Health.
Constructs
RNA samples extracted from the brain of adult mouse FVB/N
(Trizol reagent Invitrogen cat.nu15596–018) were retrotranscribed
by the SuperScript
TM First-Strand Synthesis System for RT-PCR
using oligo (dT) as a primer (Invitrogen Cat. Nu 12371–019). A
1,495 Kb cDNA (from position –46 to position+1449) fragment
encoding CB1 receptor was obtained by PCR reaction using
primers specific for the CB1. The oligonucleotides have been
designed with linkers containing consensus sequences for the
restriction enzymes PstI and Sal1 (forward PstI-CB1 CTACTG-
CAGCTCTTTCTCAGTCACGTTG; reverse SalI-CB1
TATGTCGACTTCTGGGCAGCCACAAAAG). The Pst1 and
Sal 1 restriction sites allow the in-frame directional cloning of the
CB1 cDNA into the vector pBI-G Tet Vector (Clontech cat 6150-
1 Gene Bank accession number U89933) (called pBI-G-CB1). In
the pBI-G vector, the tetO operator controls two CMV promoters
in opposite direction. One of the two promoters directs the CB1
cDNA, the other controls a reporter gene (Lac Z), allowing the
temporal and spatial expression of the transgene. The final pBI-G-
CB1 construct was mapped using restriction enzymes and fully
sequenced. The cDNA construct was linearized by restriction
enzyme digestion (BglII) and purified by phenol and chloroform
extraction and precipitated with ethanol. The DNA was
resuspended in Low Salt Buffer (0,2M NaCl, 20 mM TrisHCl,
1mM EDTA, pH 7.4) and filtered using an Elutip-D syringe
column (Whatman) and diluted in 1 to 4 ng/ml in microinjection
buffer (5 to 10 mM Tris pH 7.4, 0.1 to 0.25 mM EDTA). Purified
DNA fragments were injected into fertilized mouse eggs (FVB/N)
and then transferred into pseudo-pregnant foster mothers (C57/
BL6). Founder animals were identified by PCR using primers
specific for the Lac Z (forward GGCGTTACCCAACTTAATC,
reverse ATGTGAGCGAGTAACAACC) and Southern blot
(probe: PCR product of the Lac Z and the total plasmid used for
microinjection). F1 progeny was obtained by breeding founder
animals with the C57/BL6 mice. The transgenic line pBI-G-CB1
was crossed with the transgenic line for the tTA under the control
of the tissue-specific promoter CaMKIIa and with emizygous
CB1
+/–.
The screening of the progeny was carried out by PCR on DNA
from tail biopsy using three sets of primers. One specific for the
pBI-G vector (Lac Z), one for the tTA transgene (forward:
TTGATCACCAAGGTGCAG; reverse CTGCTCAAACTC-
GAAGTC) and the other for the Neo gene (CB1
-/- forward
ATGGGATCGGCCATTGAAC; reverse CTCGTCCTGCAG-




+/–) were mated to obtain mice
homozygous for the CB1
-/- and emizygous for the pBI-G-CB1
(
+/–) and homozygous/emizygous for CaMKII-tTA (
++;+/–)
(named Inducible Reversible CB1
-/- or IRh-CB1
-/-). Screening
was performed by PCR utilizing the following primers: forward
CAATTTGTGGTGCCTGGTG and reverse TGGATGTT-
GTCCTCGTTC.
This murine model re-expresses the CB1R only in the brain
areas where the CaMKII promoter is active (mainly the forebrain)
and knocks it down anytime by adding the tetracycline analog Dox
to the diet. The spatial and temporal expression of the transgene
was determined by following the expression of the reporter gene
Lac Z and the CB1 expression level by real-time PCR in animals
treated with Dox versus untreated animals and WT.
Lac Z Expression
Expression of Lac Z in the final transgenic line IR- CB1
-/- was
assayed by staining brain slides for B galactosidase (Lac Z) activity
[39]. Briefly, animals were sacrificed by cervical dislocation, brains
quickly removed and frozen on dry ice. Frozen sections (20mm)
were cut on a cryostat and fixed in 4% paraformaldehyde (PFA) in
phosphate buffered saline (PBS) for 15 min, incubated in X-gal
solution at room temperature overnight, and then washed with
PBS. X-gal solution had the following composition: 0.5 mM
potassium ferricyanide, 0.5mM potassium ferrocyanide, 2mM
MgCl2, 0.1% Triton-X-100 and 0.037% X-gal.
Real-time PCR
RNA samples were extracted from the prefrontal cortex,
caudate nucleus, hippocampus and cerebellum of adult mice
(IRh-CB1
-/-) after 15 days of Dox treatment, without any
treatment and WT used as controls. They were retrotranscribed
by using the SuperScript
TM First-Strand Synthesis System for RT-
PCR using random primer (Invitrogen Cat. nu 12371–019).
cDNAs were analyzed by quantitative real-time polymerase chain
reaction (Q-RT PCR) with specific primers for the genes (Mn
00432621_S1 cnr1 Applied Biosystem). Q-RT PCR reactions
were performed using the ABI Prism 7900 Fast Real Time PCR
(Applied Biosystem) with TaqMan (TaqMan PCR 2X Master mix;
Applied Biosystems).
Immunohistochemistry
Immunochemistry experiments were performed as previously
described [40]. Briefly, mice were anaesthetized with chloral
hydrate (400 mg/kg, i.p.), and transcardially perfused with 4%
paraformaldehyde and 0.1% glutaraldehyde in 0.1M phosphate-
buffered saline (PBS, pH 7.4). After repeated washing in 0.1 M
PBS, coronal sections (40 mm thick) of brain were prepared with a
vibratome and immunostaining was performed on free-floating
sections. Pre-blocking of tissue sections was performed with 10%
normal goat serum, 2.5% bovine serum albumin (BSA) and 0.2%
Triton X-100 in PBS for 1h at room temperature. Sections were
incubated for 48 h at 4uC with rabbit anti-CB1 receptor polyclonal
antibodies directed against the last 15 amino acids of rat CB1
receptor (1:2000) [41] kindly supplied by Dr. K. Mackie
Disrupted PPI in Hypomorphic CB1
-/- Mice
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35013(Department of Psychological & Brain Sciences and the Gill
Center, Indiana University). After washing in PBS-0.2% Triton X-
100, sections were incubated for 1h at room temperature with
biotinylated goat anti-rabbit IgG (1:200, Vector Laboratories,
Burlingame, CA, USA). Subsequently, sections were incubated
with Avidin Alexa Fluor
R 488 for 1 h in the dark at room
temperature, then rinsed and mounted onto Superfrost glass slides
in antifading solution with 200 mg/ml of 49,6-diamidino-2-
phenylindole (DAPI) as a nuclear counterstain. Standard control
experiments were performed by omission of either the primary or
secondary antibody and yielded no cellular labeling.
All observations were made using an Olympus IX 71
microscope (Olympus, Tokyo, Japan) equipped with 106,2 0 6
and 606 plan apochromatic oil immersion objectives (Olympus
UPlanSApo series) with an efficient chromatic correction to
minimize the focus drift between different fluorescence emissions.
Images were taken with a 12-bit cooled CCD camera (Sensicam
PCO, Kelheim, Germany) electronically coupled to a mechanical
shutter interposed between the 100-W Hg lamp and the
microscope, to avoid photo bleaching. The digital resolution of
images made with the 606objective was 0.1mm/pixel. Excitation
light was attenuated with a 6% transmittance neutral density
filter. Color compositions were made using images of antibodies
as single RGB channels. When the immunosignal was small, as
for the CB1R, the focus depth was extended by summing the
maximum intensity of several images taken at focus steps of
1 mm. Image analysis and measurements were performed using
the ImagePro Plus package (Media Cybernetics, Silver Springs,
MD, USA).
Behavioral Experiments
A total number of 87 (50 litters) male mice were used for this
purpose. All mice were 2 to 4 months old and weighed from 25 to
40 g at the beginning of the experiments. All behavioral
experiments were conducted between 11:00 AM and 3:00 PM
in sound proofed rooms. For some experiments the same animals
were used in each paradigm, and between each experimental
paradigm mice were allowed to rest at least for 1 month.
Locomotor activity was assessed as the first behavioral test.
To exclude possible aspecific effects of Dox treatment and/or
influences of sucrose (energy intake) on behavioral experiments
some mice were given either the antibiotic (n=3) or sucrose (5%)
in their water supply (n=4). Since no differences were observed in
both locomotor activity and PPI response, all of them have been
included in the analysis of the data.
Spontaneous Locomotor Activity
Mice were individually tested for motor activity under
standardized environmental conditions (light intensity with a
Digiscan Animal Activity Analyzer (Omnitech Electronics,
Columbus, Ohio). Each cage (42 cm630 cm630 cm) had two
sets of 16 photocells located at right angles to each other,
projecting horizontal infrared beams 2.5 cm apart and 2 cm
above the cage floor and a further set of 16 horizontal beams
whose height could be adapted to the size of the animals (for the
mice 12 cm above the cage floor). Basal horizontal and vertical
activities were measured as total number of sequential infrared
beam breaks in the horizontal or vertical sensors, recorded every
10 minutes, beginning immediately after placing the animals in the
cage, over a period of 90 minutes. The output data are expressed
as distance moved in cm (horizontal activity) and as number of
rearing episodes (for vertical activity), and as time (sec) spent in the
center of the arena.
Acoustic startle Response and Pre-pulse Inhibition (PPI)
Detection of acoustic startle response and PPI was performed as
described [42], in four standard non-restrictive Plexiglas cylinder
cages (3.2 cm diameter 612 cm length diameter) mounted on a
piezoelectric accelerometer platform, all in sound-attenuated
chambers with fan ventilation, connected to analogue–digital
converters (Med Associates, St. Albans, VT, USA) with a 60-dB
ambient noise level. Background noise and acoustic startle were
conveyed through two speakers placed in proximity to the startle
cage so as to produce a variation in sound intensity within 1 dB.
On the testing day, each mouse was placed in a cage for a 5-min
acclimatization period with a 70-dB white noise background,
which continued for the remainder of the session. Each session
consisted of three consecutive sequences of trials (periods). Unlike
the first and the third periods, during which mice were presented
with only five pulse-alone trials of 115 dB, the second period
consisted of a pseudorandom sequence of 50 trials, including 12
pulse-alone trials, 30 trials of pulse preceded by 73-, 76-, or 82-dB
pre-pulses (ten for each level of prepulse loudness), and eight no-
stimulus trials, where only the background noise was presented.
The duration of pulses and pre-pulses was 80 and 40 ms,
respectively. Prepulse–pulse delay amounted to 100 ms. Inter-trial
intervals were selected randomly between 10 and 15 s. Startle
amplitude values were calculated as the difference between peak-
to-peak voltage during a time window of 80 ms after stimulus
onset and peak-to-peak voltage in the 80 ms time window before
stimulus onset.
The percent (%) PPI was calculated based only on the values
relative to the second block, and using the following formula:
(100–((mean startle amplitude for prepulse+pulse trials/mean
startle amplitude for pulse-alone trials)6100).
Drugs and Treatments
Doxycycline HCl (SIGMA-ALDRICH, Italy) was dissolved in
sterile 5% sucrose solution and administered to mice in sterilized
bottles that were light protected by wrapping them with a black
adhesive paper [43]. The ad libitum solution (50 mg/ml) was freshly
prepared every 4 days, the treatment lasting 12 to 15 days.
Haloperidol (HaldolH, Janssen - Cilag, Italy) dissolved in saline was
administered intraperitonelly (i.p.) 30 min before PPI at 1 mg/kg/
10 ml.
Data Analysis
Results are expressed as the mean6SEM of n mice as specified
in the text and/or figures legend. For the PPI test, the data were
analysed as the average percent (%) PPI over the 3 prepulse
intensities tested. The significance of differences between groups
was determined by one-way or two-way analysis of variance
(ANOVA or Kruskall-Wallis) followed by Newman–Keuls or
Dunn’s Multiple Comparison or Bonferroni post-hoc comparisons
when appropriate, or Student’s t test. The threshold for significant
difference was set at p,0.05. Graphs and statistics were generated
by Graph Pad Prism 5.0 (Graph Pad Software; http://www.
graphpad.com).
Results
Generation and Characterization of IRh-CB1
-/- Mice
In Fig. 1, a schematic representation of the IRh-CB1
-/- model is
shown. Six transgenic mice were produced, three of which did not
express the transgene after crossing with the CaMKIIa–tTA
transgenic line. From the remaining three lines, we used the mice
with CB1R mRNA levels closest to physiological ones to carry out
the crosses to generate IRh-CB1
-/-. Animals with the following
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RT-PCR from total mRNA of brain IRh-CB1
-/- confirmed the
production of a full-length CB1 RNA from the transgene (data not
shown).
To validate the model, the activity of the reporter gene LacZ was
tested in IRh-CB1
-/- mice treated or untreated with Dox. As
shown in Fig. 2, b-galactosidase activity was present in all the
brain areas where LacZ expression was driven by the CaMKII
promoter, whereas a strong reduction in the activity was detected
in Dox-treated mice. Fig. 3 shows the mRNA expression levels
obtained after real time-PCR in different brain areas. Untreated
IRh-CB1
-/- mice presented levels of CB1 transgene expression of
21% in the caudatum, 49% in the hippocampus and 72% in the
prefrontal cortex in WT animals, whilst 15 days of Dox strongly
down regulated its expression in these areas. The prefrontal cortex
showed the highest expression level with respect to all other areas.
In our model, RNA transgene expression of CB1R revealed levels
ranging from 21% to 72% in different brain areas. mRNA
expression in cerebellum was absent in the IRh-CB1
-/- line under
Dox as well as without the antibiotic treatment in comparison to
WT mice (panel D), in agreement with the Lac Z data (data not
shown). In IRh-CB1
-/- immunohistochemistry experiments using
the antibody for the last 15 amino acids of the rat CB1R revealed a
low signal (Fig. 4, A–D), which was shown in detail (green) to be
diffused at cytoplasmic level by nuclear staining of DNA with
DAPI (blue), clearly contrasting with that obtained in WT mice
(Fig. 4, E–F) were the signal follows the fibers and surrounds
neuronal cells. Furthermore, the GTPcS binding assays carried
out in the some brain areas from IR- CB1
-/- resulted in only 6%
(prefrontal cortex) or 13% (striatum and hippocampus) increases of
bound GTPcS above baseline after stimulation with the CB1R
agonist WIN 55,212-2 (10 mM) (data not shown).
Even though the original construct was fully sequenced before
the production of transgenic mice, we decided to sequence the
CB1 transgene in the founder animal and in the F1 progeny.
Sequencing of the full CB1 transgene RNA revealed an
accidental single nucleotide mutation with a consequent substitu-
tion of a methionine with a threonine at position 36 of the receptor
protein (M36Th) in the extracellular N-terminal domain. Com-
putational analysis by SIFT (http://sift.jcvi.org/, [44]) revealed
that such a substitution would not compromise CB1R function.
However, some modifications in protein folding cannot be ruled
out.
Behavioral Experiments
Spontaneous motor activity. All male mice were tested for
their spontaneous motor activity expressed either as basal
horizontal (distance in cm) or vertical activity (number of rearing
episodes) analyzed over a 90-minute period in a Digiscan Animal
Activity Analyzer.
As shown in Fig. 5 (panel A) the IRh-CB1-/-, either treated or
untreated with Dox (12 days at the dose of 50 mg/ml), and CB1-/-
mice presented significantly higher traveled distances, expressed as
total distance, compared with WT animals (P,0.001, Kruskall-
Wallis test). Two-way ANOVA with repeated measures showed
the significant main effects (Fig. 5, panel C) of genotype
(F3, 368]=5.908, P=0.002), and time course (F8, 368=94.40,
P,0.0001), as well a significant time course x genotype interaction
(F24, 368=2.414, P=0.0003). In panel B and D the total number
of rearing episodes and their time course, respectively, are shown.
As for the distance travelled, a statistically significant increase was
observed in all transgenic mice compared to WT animals
(F3, 40=3.480, P=0.025). As for distance, significant effect of
time (P,0.0001), genotype (P=0.03) and genotype x time
interaction (P,0.0001) were observed for vertical movements. A
significant increase in the time spent at the center of the activity
cages (first 10 minutes test) was observed only for the CB1
-/- group
but not for the WT and the IRh-CB1
-/- groups. On the contrary
no differences were detected for the time spent at the margins for
all groups (data not shown).
Pre-pulse inhibition (PPI). The analysis of the startle
amplitude is shown in Fig. 6 (panel A). All mice independently
from genotype did not show differences (Fig. 6, panel A) in
acoustic startle response amplitude (P=0.8486). Moreover, when
analyzing PPI response in each experimental group at the 3
different prepulse intensities, we did not find significant differences
in the response to prepulse intensity within each group. Thus, the
data have been expressed as the average PPI response over the 3
prepulse intensities. On the other hand, the one-way ANOVA for
the different genotypes showed a significantly decrease in PPI (F3,
51=20.18, P,0.0001) only in IRh-CB1
-/- mice under Dox
compared with all other groups. The two-way ANOVA with
repeated measures revealed the significant main effect of genotype
(F3, 102=19.73, P,0.001), whereas neither pre-pulse intensity
Figure 1. Schematic representation of the construct for generating the IR-CB1-/-. Tetracycline-controlled transactivator (tTA) expression
was driven by the CaMKII promoter. In its active form, tTA binds to the tetO operator sequence that controls two promoters in opposite direction and
initiates expression of the CB1 and Lac Z transgenes. Expression can be inhibited by Dox as it binds to tTA, making it inactive.
doi:10.1371/journal.pone.0035013.g001
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interaction (F6, 102=1.127, NS) were significantly affected (see
Figure S1 in supporting information data). Therefore, the
reduction of PPI observed in IRh-CB1
-/-+Dox mice was
independent of the pre-pulse intensity tested.
All parameters for startle and PPI experiments (startle
amplitude P120, first 2 blocks and response to the 3 different
prepulse intensities, no pulse and peak time) have been included in
the Supporting Information data (Table S1). The reversibility of
the Dox effect on PPI values is shown in Fig. 7 (panel A). As
previously described, when CB1R expression was knocked down
by Dox, a clear significant disruption of PPI was observed after a
washout (12 days) from Dox for the treated animals, the two
groups of mice were switched in treatment assignment and the PPI
values were measured once more. As shown in the panel A the
mice previously untreated with Dox, switching off CB1Rexpres-
sion induced a significant disruption in PPI; on the contrary, the
mice previously in disruption showed, after washing out of Dox, a
complete recovery in their sensory-motor gating responses (two-
way ANOVA: treatment effect F1,19=26.42, P,0.0001). To verify
the possible involvement of the dopaminergic system in the
disrupted PPI, a further experiment was performed. One more
group of Dox-treated IRhCB1
-/- mice were injected with the
dopamine D2 receptor antagonist haloperidol (1 mg/kg i.p.
30 min. prior testing). Antagonizing dopamine D2 receptors
significantly reverted (P,0.001) the PPI disruption induced by
knocking down CB1R, with values almost returning to baseline
(Fig. 7, panel B). Interestingly, heterozygous IR-hCB1
+/–, Dox
treated and untreated, were also tested for their PPI response.
These mice, irrespective of Dox treatment, did not differ in their
response from that of the untreated homozygous mice (data not
shown).
Discussion
The present study describes the generation of CB1R conditional
and reversible knockdown hypomorphic (IRh-CB1
-/-) mice with
some interesting endophenotypes through the combination of the
Tet-off system with the classic knock-out system. Such a strategy
provides several advantages over the conventional conditional
gene-targeted or chimeric mice. The tet-off system enables the
study of mouse cnr1 gene function in a regulated manner. It allows,
through the use of the specific forebrain CaMKIIa promoter for
driving tTA expression, gene expression in a reversible and spatio-
Figure 2. Sample of B-GAL activity in both WT and IR-hCB1
-/- mice either Dox treated or untreated. The expression of the reporter gene
LacZ is visualized by b-GAL activity in the hippocampus from untreated (A) and Dox-treated (B) mice.
doi:10.1371/journal.pone.0035013.g002
Disrupted PPI in Hypomorphic CB1
-/- Mice
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35013temporal way otherwise impossible to achieve by the conventional
irreversible Cre-mediated conditional knockout system [34–35].
Whereas our model works very well in terms of modulating gene
expression of the CB1R, some limitations are present in the
protein expression (low protein synthesis). The immunohistochem-
istry experiments show an absence of the receptor from the axonal
membrane and suggest an exclusive intracellular localization [45–
46] and/or a constitutive internalization [47]. Such unexpected
results might be reasonably ascribed to the point mutation
M36Thr obtained accidentally that affects the extracellular
receptor tail. As mentioned above, IRh-CB1
-/- mice exhibit
altered endophenotypes that include increased locomotor activity
and deficits in pre-pulse inhibition of acoustic startle response.
These IRh-CB1-/- mice present hyperlocomotion similarly to the
classic CB1
-/- mice, and it may be ascribed to the unbalanced
activity of the neural population of brain circuits involved in
controlling motor behavior. Indeed both classical KO mice and
hypomorphic mice lack of CB1Rs in different parts of the
vertebrate motor system from networks responsible for the
execution of movement to planning centers in the basal ganglia
and cortex [48]. Such increased spontaneous activity in these mice
is partially in contrast with the data reported by Marsicano and
coworkers [49] where no difference in locomotor activity between
their CB1
-/- and WT mice was noted. Such lack of difference seen
in locomotor activity might be explained by the short observation
time chosen (30 min) and that in this short period the WT did not
fully habituate. However, our WT mice were less active than the
transgenic ones from the beginning of the experiment, and in
particular in the first 30 min, where a significant difference in the
motor activity (P,0.05 WT vs all transgenic groups, Newman-
Keuls Multiple Comparison Test) could be observed, with the
habituation in transgenic mice slower than WT. Furthermore,
they carried out their behavioral test during the dark phase and
this could obscure differences in activity due to a ceiling effect,
being the mice more active nocturnally [21]. Since CB1R are
mainly located on GABAergic neurons Monory and coworkers
[50], have dissected the behavioral responses to THC in
conditional knockout mouse lines lacking CB1 in different
neuronal subpopulations (principal brain neurons, GABAergic
neurons, cortical glutamatergic neurons, those expressing the
dopamine receptor D1, respectively). In their paper it has been
suggested: I, that the CB1Rs mediate many activities by different
Figure 3. Real time-PCR CB1 mRNA expression in both WT and IR-hCB1
-/- mice either Dox treated or untreated. The mRNA expression
detected by real time-PCR was measured in different brain areas from WT, untreated and Dox-treated IR-hCB1
-/- mice (n=3 for each group).
*P,0.001.
doi:10.1371/journal.pone.0035013.g003
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that those on GABAergic interneurons do not appear to mediate
the effects of THC; II, that cortical glutamatergic neurons
expressing CB1R mediate a large portion of hypolocomotor
effects of cannabinoids and III, that the simultaneous activation of
CB1Rs located on striatal neurons and glutamatergic neocortical
neurons is likely to be necessary to exert the cataleptic effect of
THC [50]. Furthermore, the other complicated interactions
between serotonergic and endocannabinoid systems [51] as well
as the finding that GABAergic neurons, specifically the b2 subunit,
possess a binding site for the endocannabinoid 2AG [52] may
differently interfere in locomotor responses in such mice.
Moreover the involvement of the HPA axis activation could not
been ruled out in the behavioral responses observed in our mice
[21,53], in particular for the different extent of thygmotaxis
showed by classical in comparison to WT and IRh-CB1
-/- mice.
The lack of difference observed in the locomotion behavior
between constitutive CB1
-/- and IRh-CB1
-/- mice, either treated
or untreated with Dox, is not surprising, since it has been recently
shown that male mice lacking CB1 receptors display decreased
voluntary running compared with their wild-type littermates,
when housed with a running wheel for several weeks. Moreover,
when the daily patterns of running behavior in mice CB1 KO
offered running wheels were compared to those of locomotor
activity in the ones housed without running wheels) only the
former, but not the latter, behavior is under the control of CB1
receptors not being affected by the absence of CB1 receptors [54].
The present study shows for the first time that ‘‘acutely’’
knocking down the CB1R expression in the IRh-CB1-/- mouse
treated with Dox is sufficient to unmask an important endophe-
notype involved in schizophrenia, i.e. the disruption of PPI.
Furthermore, the same response cannot be seen in classical CB1
-/-,
with these mice not showing any alteration in their sensory-motor
gating responses. This dichotomy might be explained by the
presence of compensatory mechanisms occurring in the constitu-
tive CB1
-/- mice and by the particular neuroanatomical circuitry
mediating the PPI response [55]. Indeed, PPI can be regulated,
and even eliminated, by subtle pharmacological manipulations at
the most rostral tip of the forebrain: i.e., PPI is mediated via the
pons and can be regulated by the forebrain [55]. In our case only
‘‘acutely’’ switching off the, although not fully expressed, receptor
in the forebrain is sufficient to affect PPI, a behavioral test that
together with motor activity is frequently used for validating
animal models of schizophrenia.
Figure 4. CB1 receptor immunoreactivity in the hippocampal formation. Representative low-magnification (4 x) showing CB1-IR throughout
the hippocampus of WT (A) and IR-hCB1
-/- (B) mice. Higher-magnification (20 x) of the CG3 displays a dense network of CB1 immunoreactive fibers in
WT mice (C) almost undetectable in IR-hCB1
-/- animals (D). Enlarged images (60x), of CG3 area showing CB1R staining (green) in throughout the
neuronal processes from WT (E) and transgenic mice (F). Nuclear staining of DNA with DAPI (blue) revealed that, contrary to the WT, in IR-hCB1
-/- the
CB1-IR diffuses into cytoplasm and almost lacks in neuronal membranes and fibers.
doi:10.1371/journal.pone.0035013.g004
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CB1 receptors, even at doses that usually antagonize the effects of
CB1 stimulation, is unable to induce PPI in either mice or rats [1],
although it is able to inhibit the disruption of PPI induced by the
dopamine D2 agonist apomorphine [27]. Moreover, it must be
underlined that the Dox-induced PPI disruption was completely
reverted when the mice underwent Dox withdrawal, i.e. when the
CB1R expression was restored. Vice versa it was again observed in
those IRh-CB1
-/- mice previously treated with vehicle alone. Such
result is peculiar of this model since the knocking down of the
CB1R is not permanent as it is for the corresponding CRE-Lox
mice [39]. Thus, the benefit of our model is represented by its
reversibility. In this it might be more interesting to investigate on
the related modifications and interactions in different brain areas
that can be obtained during such gene manipulation. One
interesting interaction is obviously with the dopaminergic system
and, in Dox
+ IRh-CB1
-/- mice; the administration of 1 mg/kg
haloperidol completely antagonized the impairment of sensorimo-
tor gating, consistent with the involvement of that neurotransmit-
ter system. Future experiments for both behavioral and gene
expression alterations in such crucial neuronal systems, as well as
for the other ones (GABAergic, Glutamatergic and so on) will be
needed and in particular for the glutamatergic system that is
supposedly being disregulated (hypofunction) in schizophrenia
[56–57] However, since the expression of the CB1R in
hypomorphic IRh-CB1
-/- mice is very low, the PPI disruption
observed might also be attributed to CB1R intracellular activation
[47,58] and thus it deserves more experiments to investigate other
Figure 5. Motor activity in IRh-CB1
-/-, CB1
-/- and WT mice. In panel A and C, the total distance (cm) traveled in 90 min and related time course,
respectively, are depicted. The vertical activity expressed as total number of rearing episodes and the time course are illustrated in panel B and D,
respectively. All data represent the mean6S.E.M. of WT (n=9), CB1
-/- (n=8), IRh-CB1
-/- (n=22) and IRh-CB1
-/-+ Dox (n=11) mice. For the rearing
behavior for some mice the data have been lost (not recorded by the apparatus) and thus the number of mice for the two latter groups is 18 and 9,
respectively. ***P,0.001 and *P,0.05 vs WT mice (Dunn’s Multiple Comparison test for total distance, and Newman-Keuls Multiple Comparison test
for all the others).
doi:10.1371/journal.pone.0035013.g005
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kinase phosphorylation and decrease in cAMP production). The
observed M36Thr substitution at the N-tail could indeed prevent
their complete localization at the plasma membrane.
Contrary to the other members of the GPCRs, the CB1R has
an exceptionally long extracellular N-terminal domain (N-tail) of
116 amino acids but without the typical cleavable signal sequence.
It has been suggested that the long N-tail affects the biosynthesis of
the receptor and its insertion into the endoplasmic reticulum (ER)
membrane [59]. Indeed, when the long N-tail is not efficiently
translocated across the ER membrane, the CB1R undergoes rapid
degradation by proteasomes, leading to its low expression at the
plasma membrane; on the contrary, adding a signal peptide at the
N-terminus of CB1R or shortening the long N-tail increases
stability and cell surface expression [59]. The M36Thr substitution
could then enhance the degradation rate by proteasomes or affect
in some way receptor binding to the CP-55,940 and account for
the low protein expression in the IRh-CB1
-/- mice. Alternatively,
since no cleavable signal sequence is present at the N terminus, the
point mutation in the IRh-CB1
-/- mice might change the folding
behavior of the N-terminal domain, an important factor in the
topogenesis of signal-anchor proteins [60]. Usually, a GPCR
resides at the cell surface and, following activation, undergoes
phosphorylation, desensitization, internalization and finally either
degradation or recycling [61]. Moreover, while it is internalized,
the receptor may also contribute to activate signaling cascades
such as those first identified for the b2-adrenergic receptor and
more recently for the angiotensin II 1A receptor [58,62–63].
Immunocytochemical staining both in cell cultures and in neurons
has demonstrated that CB1Rs constitutively internalize in their
native state [64] although their trafficking resulted to be highly
complex [65]. It has been recently described by Rozenfeld and
Devi [58] that transfected and tagged CB1Rs preferably localize at
the plasma membrane, whereas endogenous receptors are
intracellular.
The lipophilic properties of the ligand are crucial for its ability
in crossing the membrane and activate intracellular receptors [46–
47]. It is likely that GPCRs which bind a lipophilic ligand may be
activated at intracellular compartments. Among GPCRs, the
CB1R binds and is activated by the lipid derivatives such as
anandamide and 2-AG [58]. These endogenous cannabinoids are
extremely lipophilic and easily diffuse through the plasma
membranes [59]. Moreover, endocannabinoids are actively
uptaken into the intracellular compartment although no specific
transporters are yet identified [46] and stimulate intracellular
CB1R [66]. In our case, it can be also hypothesized that the point
mutation in the receptor preferentially shifts the equilibrium to the
internalized form.
Figure 6. Startle response and percentage of PPI in IR-hCB1
-/-, CB1
-/- and WT mice: effect of Dox treatment. The startle amplitude (panel
A) and % of PPI (panel B) are the mean6S.E.M. of WT (n=13), CB1
-/- (n=13), IR-hCB1
-/- (n=15) and IR-hCB1
-/- Dox (n=14) mice. For PPI the data are
expressed as the average PPI response over the 3 prepulse intensities (see supplemental files for the figure illustrating PPI by prepulse intensity).
***P,0.0001 IR-hCB1
-/- Dox vs all other groups (Newman-Keuls Multiple Comparison test).
doi:10.1371/journal.pone.0035013.g006
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-/- mice without a point
mutation is in progress and will be utilized to validate that the
‘‘acute’’ knockdown of the receptor after Dox treatment accounts
for the PPI disruption observed in the present study. However, the
lack of alteration of PPI in canonical CB1
-/- mice must be stressed,
although a PPI disruption in other ‘‘cre-lox’’ conditional CB1
-/-
mice [34–35] cannot be ruled out, no such kinds of experiments
have been performed to date.
Recently, the deletion of CB2r in CB2
-/- mice has been reported
to induce schizophrenia-related behaviors, including PPI disrup-
tion and reduced motor activity [10]. In this paper, the distinctive
profiles between patients with bipolar disorder and schizophrenia
were used in support of their CB2
-/- mice as a model of
schizophrenia. They suggested that mutant mice with motor
hyperactivity and reduced PPI, similar to patients [67–68], were
more closely related to animal models of bipolar disorder than
schizophrenia. Since our hypomorphic IRh-CB1
-/- mice showed
spontaneous increased motor activity and the ‘‘acute’’ knockdown
of CB1R expression induced by Dox impaired PPI, such a
suggestion deserves further studies and a more complete
behavioral and biochemical characterization using the still in-
progress full IR-CB1
-/- mice.
Conclusions: In the classic CB1
-/- mice, there were no changes
in PPI, but in our IRh-CB1-/- mice under Dox treatment, PPI was
disrupted, which was easily reversible after withdrawing the Dox
or after Haloperidol treatment. We describe for the first time the
clear involvement of CB1R in PPI disruption, which might shed
light on the contradictory data reported up to now. Although
hypomorphic due to a de novo point mutation, our IRh-CB1-/-
mice might represent a powerful tool for studying the physiological
and pathological roles of the cannabinoid system given its
reversibility in gene expression, and better investigate the complex
interaction between the endocannabinoids and the other neuro-
transmitters. However, given that most of the disrupted genes are
involved in neuronal plasticity, glutamatergic or dopaminergic
function and synaptogenesis [2,69] and multiple susceptibility
genes act synergistically, as well as in conjunction with epigenetic
processes and early-life environmental adverse effects, sophisticat-
ed strategies are needed for the development of novel schizophre-
nia models. Recently it has been proposed that rather than
focusing on a mutation or an altered function of only a single gene,
a better strategy is produce double or triple genetically modified
mice to explore the interacting effect between different genes [2].
Supporting Information
Figure S1 Percent of PPI in IR-hCB1-/-, CB1-/- and WT
mice at different prepulse intensities: effect of Dox
treatment. The % of PPI at the different prepulse intensities are
the mean6S.E.M. of WT (n=13), CB1-/- (n=13), IR-hCB1-/-
(n=15) and IR-hCB1-/- Dox (n=14) mice. The two-way
ANOVA with repeated measures revealed the significant main
effect of genotype (F3,102=19.73, P,0.001), whereas neither pre-
pulse intensity (F 2,102=0.8939, NS), nor genotype x pre-pulse
intensity interaction (F6,102=1.127, NS) were significantly
affected.
(TIF)
Table S1 Values represent mean±S.E.M. for each
parameter (for further details, see text). Mean SA, mean
startle amplitude for the whole trial sequence; First block, mean
startle amplitude for the first half of the session; Second block,
mean startle amplitude for the second half of the session; PP3, PP6
and PP12, mean prepulse levels at the different intensities; No
pulse, mean no pulse, expressed as percent of whole trial
sequences; Peak t., mean of the latency to the peak of startle for
the whole trial sequence.
(DOCX)
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Figure 7. Percentage of PPI in IR-hCB1
-/- mice under different
conditions. All values represent the mean6S.E.M. Panel A: reversibility
of Dox-induced disruption of PPI. Two groups of IR-hCB1
-/- mice have
been randomly assigned to vehicle group (dotted color, n=6) or Dox
group (plain color, n=7) and then tested for PPI (Exp. 1). Dox
administration lasted 12 days, and extra 12 days served for the washout,
after which the schedule was repeated by switching the treatments (i.e.
Dox given to previous No-Dox treated mice, and vice versa) (Exp. 2).
Panel B: Dox-induced disruption of PPI is antagonized by haloperidol
(1 mg/kg i.p., 30 min before PPI session).
doi:10.1371/journal.pone.0035013.g007
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